Safety and effectiveness of isavuconazole in real-life non-neutropenic patients
There is a notable change in the profile of patients with invasive fungal infections (IFI): there has been a progressive rise of such infections in non-neutropenic population (i.e., COVID-19, influenza, biologic agents, corticosteroids, cancer, chronic obstructive pulmonary disorder [COPD] or cirrhosis) [1 –3]. However, information concerning the management of non-neutropenic patients with IFI remains limited. Caution should be exercised before these patients are treated like those who are neutropenic, given a considerable variability in pathogenesis and clinical manifestations of IFI [4].
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Patricia Monz ó-Gallo, Carlos Lopera, Ana M Badía-Tejero, Marina Machado, Julio García-Rodríguez, Pablo Vidal-Cortés, Esperanza Merino, Jorge Calderón, Jesús Fortún, Zaira R. Palacios-Baena, Javier Pemán, Joan Roig Sanchis, Manuela Aguilar-Guisad Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Obstructive Pulmonary | Cirrhosis | Corticosteroid Therapy | COVID-19 | Fungal Infections | Infectious Diseases | Influenza